Bristol Myers Squibb to acquire MyoKardia for access to CVD treatment
Category: #health  By Nikita Chaurasia  Date: 2020-10-07
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Bristol Myers Squibb to acquire MyoKardia for access to CVD treatment

 

  • BMS intends to acquire the biotech firm for USD 13 billion.
  • The potential drug of MyoKardia will be sent for FDA approval during Q1 of 2021.

Bristol Myers Squibb (BMS), an American pharmaceutical company, reportedly announced its plans to acquire MyoKardia Inc., a clinical-stage biotechnology firm.

Sources close to the matter stated that BMS intends to acquire the biotech firm owing to its innovative approach for treating cardiovascular diseases. Bristol Myers revealed that it would allot USD 13 billion for MyoKardia’s acquisition.

Giovanni Caforio, CEO of BMS, reportedly said that MyoKardia’s innovative approach for cardiovascular disease treatment makes it an important firm in the pharmaceutical sector. He further added that mavacamten, which is a potentially a groundbreaking drug for the treatment of the severe obstructive HCM condition, is the lead asset for MyoKardia.

For those unfamiliar, hypertrophic cardiomyopathy, or obstructive HCM, is a chronic heart condition which has a high morbidity. The disorder is most often seen in individuals in the age group of 40-50, and only one in four individuals with obstructive HCM have been diagnosed.

In this context, MyoKardia has developed potential therapies to fight cardiovascular disorders and claims that its experimental medicine, mavacamten, for treating obstructive hypertrophic cardiomyopathy has met all its phase three primary and secondary endpoints.

In fact, the company expects to send the experimental mavacamten for approval by the Food and Drug Administration (FDA) and is likely to be a long-term growth driver for the biotech firm.

Reportedly, Bristol-Myers Squibb’s stock during Monday's session increased by 1% to USD 59.20. However, the company's shares are down more than 7 percent as of 2020 and expects MyoKardia to raise profits by the year 2023, sources claimed.

Meanwhile, MyoKardia stock prices soared by 59% and ended nearly five points from the USD 225 bid price of Bristol Myers after the announcement of its acquisition by BMS.

Source- https://www.cnbc.com/2020/10/05/bristol-myers-ceo-a-potentially-revolutionary-drug-in-myokardia-deal.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...